TGFB1 and idiopathic pulmonary fibrosis: To further contextualize these findings, the inhibition of TGF-β1 signaling observed with GDP parallels the mechanism targeted by clinical antifibrotic agents such as pirfenidone, which is currently approved for idiopathic pulmonary fibrosis and under investigation for hepatic fibrosis.